Innate Antibacterial Activity in Female Genital Tract Secretions Is Associated with Increased Risk of HIV Acquisition

Rebecca Pellett Madan, Lindi Masson, Jessica Tugetman, Lise Werner, Anneke Grobler, Koleka Mlisana, Yungtai Lo, Denise Che, Kelly B. Arnold, Salim S. Abdool Karim, Jo-Ann S. Passmore, and Betsy C. Herold

Abstract

Greater inhibitory activity against Escherichia coli and levels of human β defensin (HBD)-2 in genital tract secretions predicted HIV acquisition in women in the HPTN 035 trial. We investigated whether higher levels of E. coli inhibitory activity and antimicrobial peptides in cervicovaginal lavage (CVL) samples predicted HIV acquisition in women in the CAPRISA 002 Acute Infection Study. E. coli inhibitory activity and antimicrobial peptides were quantified in CVL from a subset of CAPRISA 002 participants who did not seroconvert (n = 39) and from seroconverting women prior to infection (n = 17) and during acute infection (n = 11). Women who acquired HIV had significantly greater preinfection CVL E. coli inhibitory activity (p = 0.01) and HBD-1 levels (p = 0.02) compared to women who remained uninfected. Preinfection E. coli inhibitory activity remained significantly associated with seroconversion following adjustment for the presence of bacterial vaginosis (OR 1.45; 95% CI 1.07, 1.97). Partial least squares discriminant analysis confirmed that preinfection CVL E. coli inhibitory activity, together with higher CVL concentrations of HBD-1 and secretory leukocyte protease inhibitor, distinguished seroconverters from nonseroconverters with 67% calibration accuracy. CVL concentrations of human neutrophil peptides (HNP) 1–3 increased significantly with acute infection (p = 0.001) and correlated with plasma viral set point (r = 0.66, p = 0.03). E. coli inhibitory activity in genital tract secretions could provide a biomarker of HIV risk. The correlation between HNP 1–3 and viral set point merits further investigation of the relationship between mucosal inflammation during early HIV infection and disease progression.

Introduction

The ability of female genital secretions (FGS) to inhibit Escherichia coli growth in vitro may reflect contributions from molecules secreted by epithelial and immune cells, such as defensins and secretory leukocyte protease inhibitor (SLPI), and molecules secreted by the genital tract microbiota. However, the clinical relevance of E. coli inhibitory activity and the in vivo role of antimicrobial peptides in preventing genital tract infections and HIV are not well defined. Antimicrobial peptides such as defensins and cathelicidins may paradoxically increase the risk of HIV acquisition, transmission, and disease progression by promoting mucosal inflammation and target cell recruitment to the genital mucosa. Higher FGS concentrations of human neutrophil peptides (HNP) 1–3 and the cathelicidin LL-37 were independently associated with increased risk of HIV acquisition in a cohort of female sex workers in Kenya; it was hypothesized that higher concentrations of HNP 1–3 and LL-37 potentiated mucosal inflammation and target cell recruitment.

In a substudy of the HPTN 035 trial, in which women at risk for HIV seroconversion were randomized to receive one of two topical HIV preexposure prophylaxis products (BufferGel or PRO 2000), placebo gel, or no gel, detectable
human β defensin (HBD)-2 and higher E. coli inhibitory activity in FGS were associated with increased risk of HIV seroconversion [HBD-2 odds ratio (OR) 2.39; 95% CI 1.29, 4.41 and E. coli OR 1.22; 95% CI 1.04, 1.43]. However, samples were available from only eight seroconverting women from the HPTN 035 trial substudy, and plasma viral set point data were not available to assess the relationship between E. coli inhibitory activity, antimicrobial peptides, and HIV progression.

The CAPRISA 002 Acute Infection Study, a prospective, observational study of uninfected women at high risk for HIV infection in KwaZulu-Natal, South Africa, reported that FGS inflammatory cytokine concentrations during acute infection were associated with higher viral set point and faster CD4+ T cell depletion at 12 months postinfection.10,11 While these studies suggested that genital inflammatory cytokine markers predicted more rapid HIV disease progression, they did not investigate antimicrobial peptide profiles or E. coli inhibitory activity. The objective of this study was to investigate the relationship between HIV acquisition risk and FGS E. coli inhibitory activity and antimicrobial peptides among a subset of women who participated in the CAPRISA 002 Acute Infection Study. Furthermore, we investigated whether FGS E. coli inhibitory activity and antimicrobial peptide concentrations were associated with plasma viral load set point, a correlate of rate of HIV disease progression.

Materials and Methods

Study subjects

This study was approved by the University of KwaZulu-Natal and the University of Cape Town Ethics Committees and by the Albert Einstein College of Medicine Institutional Review Board. A subset of women who participated in the CAPRISA 002 Acute Infection Study who had available CVL samples was included in this study.9 CAPRISA 002 participants attended monthly follow up visits for a maximum of 24 months. CVL (10 ml normal saline wash) was collected at enrollment into CAPRISA 002 and following HIV acquisition at the earliest time point when HIV infection was diagnosed.9 Time of HIV infection in the CAPRISA 002 Acute Infection Study was defined as the midpoint between the last negative HIV antibody test and the first positive antibody test or as 14 days prior to the first detectable plasma HIV-1 RNA on the same day as a negative HIV antibody test. Plasma viral load set point was defined as the moving average of women by the Wilcoxon signed-rank test. Categorical variables were analyzed by McNemar’s tests. Spearman’s correlation coefficients were calculated to assess potential associations between continuous variables. All tests for statistical significance were two-sided, and p values < 0.05 were considered significant. Logistic regression models were used to assess the effects of variables identified in univariate analysis on risk of seroconversion.

Partial least squares discriminant analysis (PLSDA) was used to evaluate the antimicrobial peptide and E. coli inhibitory activity profiles that best distinguished between seroconverters and nonseroconverters.15,16 PLSDA utilizes covariance to identify linear combinations of independent variables (latent variables) that best differentiate between groups of interest. Every participant sample was assigned a
score, which was then visualized in the latent variable space (score plots). Latent variable loadings (loadings plots) were then used to identify multivariate combinations of individual variables associated with seroconversion. To reduce the risk of overfitting, only markers with a variable importance projection (VIP) score of >1 were included. All data were normalized with mean centering and variance scaling. Cross-validation was performed by iteratively excluding subsets of data in groups of four to five during model calibration, then using excluded data samples to test model predictions. Orthogonal signal correction was used to improve model interpretability.

Results

Description of study subjects

The women who contributed samples to this study were all urban, Zulu-speaking women from KwaZulu-Natal, South Africa. Demographic details of the full cohort were previously published.9 The prevalence of BV by Nugent’s score was similarly high between seroconverters at the preinfection time point (n = 17) and nonseroconverters (n = 39) (64.7% vs. 61.5%; p = 0.75) were also similar between seroconverters and nonseroconverters (Table 1). None of the women reported use of oral contraceptive pills. The proportions of women with HSV-2 seropositivity, chlamydia, gonorrhea, or trichomoniasis did not differ significantly between preinfection seroconverters and nonseroconverters (Table 1). HSV DNA was not detected in preinfection seroconverter vulvovaginal swabs but was detected in four swabs from nonseroconverters (p = 0.30).

For the 11 seroconverting women who had CVL available at both the preinfection and acute infection time points, the median Nugent score was eight for both time points (p = 0.22), and the proportions of women with BV did not differ significantly (72.7% vs. 90.9%, respectively; p = 0.50). One woman was diagnosed with chlamydia preinfection, two women were diagnosed with trichomoniasis preinfection, and no women were diagnosed with chlamydia or trichomoniasis at the acute infection time point (p = 1.0 for chlamydia, p = 0.47 for trichomoniasis). Although no women at the preinfection time point had gonorrhea, five women had gonorrhea during their acute infection visit (p = 0.04). Ten of the 11 women were HSV-2 seropositive at the preinfection time point, and all 11 women were HSV-2 seropositive by the acute infection time point (p = 1.0); no women had detectable HSV shedding. The median plasma HIV-1 viral load at acute infection was 360,000 copies/ml (IQR 41,600–621,000), and the median CD4+ T cell count was 435 cells/μl (IQR 201–974). The median plasma viral load set point at 52 weeks postinfection was

### Table 1. Distribution of Subject Characteristics and Logistic Regression Estimate for HIV Acquisition Risk

<table>
<thead>
<tr>
<th>Subject characteristics†</th>
<th>Seroconverters (n = 17)</th>
<th>Nonseroconverters (n = 39)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable hormonal contraceptive use, number positive (%)</td>
<td>5 (29.4)</td>
<td>10 (25.6)</td>
<td>0.75</td>
</tr>
<tr>
<td>Nugent score (median, IQR)</td>
<td>7 (5–8)</td>
<td>8 (3–9)</td>
<td>0.84</td>
</tr>
<tr>
<td>Bacterial vaginosis,² number positive (%)</td>
<td>11 (64.7)</td>
<td>24 (61.5)</td>
<td>0.82</td>
</tr>
<tr>
<td>Herpes simplex virus-2 IgG, number positive (%)</td>
<td>15 (88.2)</td>
<td>34 (87.2)</td>
<td>1.0</td>
</tr>
<tr>
<td>Chlamydia trachomatis NAAT, number positive (%)</td>
<td>1 (5.9)</td>
<td>3 (7.7)</td>
<td>1.0</td>
</tr>
<tr>
<td>Neisseria gonorrhoeae NAAT, number positive (%)</td>
<td>0 (0)</td>
<td>2 (5.1)</td>
<td>1.00</td>
</tr>
<tr>
<td>Trichomonas vaginalis NAAT, number positive (%)</td>
<td>4 (23.5)</td>
<td>8 (20.5)</td>
<td>1.00</td>
</tr>
<tr>
<td>% Inhibition of Escherichia coli (mean±SD)</td>
<td>54.44±27.99 (n = 16)</td>
<td>34.11±17.92 (n = 38)</td>
<td>0.01</td>
</tr>
<tr>
<td>Total protein³ (mean±SD)</td>
<td>2.39±0.33</td>
<td>2.33±0.34 (n = 38)</td>
<td>0.56</td>
</tr>
<tr>
<td>SLPI³ (mean±SD)</td>
<td>5.4±0.63</td>
<td>5.17±0.54</td>
<td>0.16</td>
</tr>
<tr>
<td>HNP 1–3³ (mean±SD)</td>
<td>4.29±0.76</td>
<td>4.19±0.59</td>
<td>0.58</td>
</tr>
<tr>
<td>HBD-1³ (mean±SD)</td>
<td>3.39±0.4</td>
<td>3.1±0.42</td>
<td>0.02</td>
</tr>
<tr>
<td>HBD-2³ (mean±SD)</td>
<td>3.48±0.95</td>
<td>3.72±0.6</td>
<td>0.25</td>
</tr>
<tr>
<td>HBD-3³ (mean±SD)</td>
<td>2.93±0.49</td>
<td>2.85±0.46</td>
<td>0.56</td>
</tr>
</tbody>
</table>

Logistic regression estimate for increased risk of HIV acquisition

<table>
<thead>
<tr>
<th>Variable/effect</th>
<th>Odds ratio</th>
<th>95% confidence interval</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial vaginosis⁴</td>
<td>1.5</td>
<td>0.36–6.38</td>
<td>0.58</td>
</tr>
<tr>
<td>% Inhibition of E. coli⁵</td>
<td>1.45</td>
<td>1.07–1.97</td>
<td>0.02</td>
</tr>
<tr>
<td>HBD-1⁶</td>
<td>4.43</td>
<td>0.82–23.83</td>
<td>0.08</td>
</tr>
</tbody>
</table>

1Baseline characteristics of seroconverting subjects (prior to infection) and nonseroconverting subjects.
2Diagnosis by Nugent’s score.
3Quantified from cervicovaginal lavage fluid and expressed as log10 (µg/ml) units (total protein) or as log10 (pg/ml) units (SLPI, HNP 1–3, HBD 1–3).
4Presence or absence of bacterial vaginosis by Nugent’s score.
5Estimated increased risk of HIV acquisition for every 10% increase in bactericidal E. coli activity.
6Estimated increased risk of HIV acquisition for every log10 unit increase in concentration of HBD-1.

IQR, interquartile range; NAAT, nucleic acid amplification test; SD, standard deviation; SLPI, secretory leukocyte protease inhibitor; HNP, human neutrophil peptides; HBD, human β defensin.
56,033 copies/ml (IQR 3,162–195,133). In CVL, HIV-1 RNA was detected in 4/10 (40%) acutely infected samples (one sample was not available for testing) with a median viral load of 1,110 copies/ml (IQR 199.8–1,614).

**Preinfection E. coli inhibitory activity was higher in seroconverters than nonseroconverters and was associated with HIV acquisition risk**

Preinfection mean CVL *E. coli* inhibitory activity was significantly higher in seroconverters compared to nonseroconverters [54.4% ± standard deviation (SD) 28.0 vs. 34.1% ± 17.9; p = 0.01] (Table 1). In addition, mean CVL concentrations of HBD-1 were significantly higher in seroconverters compared to nonseroconverters [3.4 log10 (pg/ml) units ± SD 0.4 vs. 3.1 ± 0.4; p = 0.02]. There were no significant differences in CVL concentrations of protein, HBD-2, HBD-3, HNP 1–3, or SLPI between seroconverters and nonseroconverters.

In a logistic regression model that adjusted for the presence of BV, the odds of HIV acquisition increased 1.45-fold for every 10% increase in *E. coli* inhibitory activity (OR 1.45; 95% CI 1.07, 1.97; p = 0.02) (Table 1). Each log10 unit increase in CVL HBD-1 concentration was associated with a 4.43 times greater risk of HIV acquisition (OR 4.43; 95% CI 0.82, 23.83; p = 0.08); however, this result was of borderline statistical significance.

**Higher CVL E. coli inhibitory activity, HBD-1, and SLPI were associated with HIV seroconversion by PLSDA**

PLSDA was used to determine which combinations of preinfection variables were most useful for classifying women as potential HIV seroconverters or nonseroconverters. CVL *E. coli* inhibitory activity, together with concentrations of SLPI and HBD-1, classified women as those who subsequently seroconverted versus those who did not with 67% calibration accuracy and 64% cross-validation accuracy (Fig. 1a). The first two latent variables in this model captured 86% of the variance in the data set. Examination of the loadings plot indicated that latent variable 1 (LV1) best differentiated the preinfection group from those who remained uninfected, and correspondingly the seroconverter (negative scores on LV1; Fig. 1a) profile was associated with elevated CVL *E. coli* inhibitory activity, SLPI, and HBD-1 (all negatively loaded on LV1, Fig. 1b). The combined model including CVL *E. coli* inhibitory activity, SLPI, and HBD-1 performed slightly better in classifying women as seroconverters or nonseroconverters than a model that used *E. coli* inhibition alone (32% calibration error for combined vs. 39% calibration error for *E. coli* inhibition alone, data not shown).

**Acute HIV infection was associated with increased human neutrophil peptides but decreased SLPI concentrations in CVL**

Mean CVL HNP 1–3 levels increased significantly from preinfection to acute infection [4.2 log10 (pg/ml) units ± SD 0.9 vs. 5.3 ± 0.7; p = 0.001] (Fig. 2), while mean concentrations of SLPI in CVL were significantly lower during acute infection.

**FIG. 1.** Scores and loadings plots for partial least squares discriminant analysis (PLSDA) model. (a) A PLSDA model using cervicovaginal lavage (CVL) *E. coli* inhibition and concentrations of human β defensin (HBD)-1 and secretory leukocyte protease inhibitor (SLPI) in samples prior to HIV infection classified women as seroconverters or nonseroconverters with 67% accuracy (red: women who acquired HIV; blue: women who remained uninfected). (b) Latent variable 1 separated women who acquired HIV from those who remained uninfected. *E. coli* inhibition, HBD-1, and SLPI were all negatively loaded on LV1, suggesting they were positively associated with HIV acquisition.

**FIG. 2.** Comparison of Nugent scores, cervicovaginal lavage (CVL) *E. coli* inhibitory activity, and CVL concentrations of secretory leukocyte protease inhibitor (SLPI), human neutrophil peptides (HNP) 1–3, human β defensin (HBD)-2, HBD-1, and protein from 11 seroconverting women preinfection and during acute infection. CVL *E. coli* inhibitory activity was unavailable for one woman at the preinfection time point.
compared to preinfection \(4.8 \log_{10} \text{(pg/ml)} \text{ units} \pm \text{SD} 0.76 \text{ vs.} 5.5 \pm 0.54; p = 0.02\). Mean CVL \(E. \ coli\) inhibitory activity increased from preinfection to acute infection, but this increase did not reach statistical significance \((56.1\% \pm 35.6 \text{ vs.} 74.6\% \pm 10.1; p = 0.13)\). Mean Nugent scores and levels of protein, HBD-2, and HBD-1 did not differ significantly between preinfection and acute infection (Fig. 2). Samples were not available for HBD-3 quantification in the acute infection group. Five women in the acute infection group had gonorrhea at the time of sample collection. However, CVL mean \(E. \ coli\) inhibition and concentrations of protein, SLPI, and defensins did not differ significantly between acute infection samples collected from women with and without gonorrhea \((p > 0.05\) for all, data not shown).

\(E. \ coli\) inhibitory activity and antimicrobial peptide concentrations were elevated in acute infection CVL samples with detectable HIV-1 RNA

Mean \(E. \ coli\) inhibitory activity \((82.25\% \pm \text{SD} 6.24 \text{ vs.} 68.43 \pm 5.38; p = 0.003)\) and concentrations of HBD-1 \((4.28 \pm \text{SD} 0.33 \text{ vs.} 3.33 \pm \text{SD} 0.33; p = 0.002)\) and HBD-2 \((4.18 \pm \text{SD} 0.36 \text{ vs.} 2.92 \pm \text{SD} 0.36; p < 0.001)\) were significantly higher in the four acute infection CVL samples with detectable HIV-1 RNA compared to the six samples without detectable HIV-1 RNA (Table 2). Mean concentrations of HNP 1–3 and SLPI were also higher in CVL samples with detectable HIV-1 RNA, although these differences were not significant.

CVL defensin concentrations during acute infection correlated with \(E. \ coli\) inhibitory activity and plasma viral load set point

CVL \(E. \ coli\) inhibitory activity at acute infection correlated positively with CVL concentrations of protein \((r = 0.71, p = 0.02)\), HBD-1 \((r = 0.61, p = 0.05)\), and HBD-2 \((r = 0.91, p = 0.001)\). A trend toward a positive correlation between CVL \(E. \ coli\) inhibitory activity at acute infection and CVL concentrations of HNP 1–3 \((r = 0.49, p = 0.13)\) and SLPI \((r = 0.57, p = 0.07)\) was observed. Of note, significant correlations between CVL \(E. \ coli\) inhibitory activity and antimicrobial peptides were not detected in samples from nonseroconverting women or in seroconverting women at the preinfection time point. Acute infection CVL concentrations of HNP 1–3 correlated positively and significantly with viral set point \((r = 0.66, p = 0.03)\).

**Table 2. Antimicrobial Peptide Concentrations in Cervicovaginal Lavage Fluid Samples with Detectable or Nondetectable HIV RNA During Acute HIV Infection**

<table>
<thead>
<tr>
<th></th>
<th>Detectable HIV RNA (n = 4)</th>
<th>Nondetectable HIV RNA (n = 6)</th>
<th>(p) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVL HIV RNA viral load (copies/ml), median (IQR)</td>
<td>1,110 (199.8–1,624)</td>
<td>68.43 ± 5.38</td>
<td>0.003</td>
</tr>
<tr>
<td>% Inhibition of (E. \ coli) (mean ± SD)</td>
<td>85.25 ± 6.24</td>
<td>85.25 ± 6.24</td>
<td>0.18</td>
</tr>
<tr>
<td>Total protein (^1) (mean ± SD)</td>
<td>2.69 ± 0.18</td>
<td>2.15 ± 0.73</td>
<td>0.06</td>
</tr>
<tr>
<td>SLPI (^1) (mean ± SD)</td>
<td>5.37 ± 0.20</td>
<td>4.5 ± 0.79</td>
<td>0.15</td>
</tr>
<tr>
<td>HNP 1–3 (^1) (mean ± SD)</td>
<td>5.74 ± 0.19</td>
<td>5.06 ± 0.84</td>
<td>0.002</td>
</tr>
<tr>
<td>HBD-1 (^1) (mean ± SD)</td>
<td>4.28 ± 0.33</td>
<td>3.33 ± 0.36</td>
<td>0.001</td>
</tr>
<tr>
<td>HBD-2 (^1) (mean ± SD)</td>
<td>4.18 ± 0.36 (n = 3)</td>
<td>2.92 ± 0.36</td>
<td>0.001</td>
</tr>
</tbody>
</table>

\(^1\)Quantified from CVL fluid and expressed as \(\log_{10} \text{(pg/ml)} \text{ units} \) (total protein) or as \(\log_{10} \text{(pg/ml)} \text{ units} \) (SLPI, HNP 1–3, HBD 1–3). SLPI, secretory leukocyte protease inhibitor; HNP, human neutrophil peptides; HBD, human \(\beta\) defensin.

**Discussion**

In this study of women enrolled in the CAPRISA 002 study, higher \(E. \ coli\) inhibitory activity and HBD-1 in CVL were associated with increased risk of HIV acquisition. These results are consistent with the findings of a substudy of HPTN 035, in which higher levels of \(E. \ coli\) inhibitory activity and HBD-2 in FGS were associated with a higher risk of HIV acquisition among eight seroconverting women, and indicate that \(E. \ coli\) inhibitory activity may provide a biomarker of HIV acquisition risk.

The precise mediators of \(E. \ coli\) inhibitory activity in FGS have not yet been elucidated. It is likely that the relative contributions from vaginal microbiota and host-derived soluble immune mediators at the genital mucosa differ between distinct populations of women. In a prior study of 99 U.S. women who did not have an STI or BV and who were at low risk for HIV acquisition, \(E. \ coli\) inhibitory activity did not correlate with CVL concentrations of defensins and other host-derived molecules. Instead, proteomic studies from five participants with CVL inhibition >90% showed that this activity was associated with surface proteins specific to *Lactobacillus crispatus* and *L. jensenii*. Vaginal microbiota data are not yet available for the women included in our study. However, the high Nugent scores among participants in this study, coupled with the observed correlations between defensins and \(E. \ coli\) inhibitory activity during acute HIV infection, suggest that among women with a paucity of lactobacilli, \(E. \ coli\) inhibitory activity may represent defense influx and mucosal inflammation. The observed associations between defensins, CVL \(E. \ coli\) inhibitory activity, and HIV seroconversion merit further investigation in prospective studies that utilize protein mass spectrometry of FGS to identify the precise mediators that confer HIV risk.

We also used PLSDA to identify relationships between CVL \(E. \ coli\) inhibitory activity and antimicrobial peptides that were most associated with HIV seroconversion and found that seroconversion was most associated with a multivariate profile that included higher CVL \(E. \ coli\) inhibition, HBD-1, and SLPI. Moreover, we observed a trend toward higher SLPI concentrations in acute infection CVL samples with detectable HIV-1 RNA compared to samples without detectable HIV-1 RNA. Taken alone, the weak association between higher CVL concentrations of SLPI and HIV seroconversion and detectable HIV-1 RNA is somewhat surprising. SLPI exerts activity against HIV in vitro, and prior...
studies have identified associations between lower SLPI concentrations and HIV seroconversion risk in larger populations. It is possible that higher levels of HIV-1 RNA in the genital tract may induce epithelial cell expression of SLPI, and the association between higher SLPI levels preinfection and HIV seroconversion risk could represent HIV-1-induced expression of SLPI by epithelial cells in the setting of repeated HIV exposure from sexual partners.

Although defensins have potent anti-HIV activity ex vivo, we identified higher HBD-1 concentrations in pre-infection seroconverters compared to nonseroconverters, and acute infection CVL samples with detectable HIV-1 RNA had significantly higher concentrations of HBD-1 and HBD-2 expression may be induced by inflammatory stimuli and by HIV-1 Tat activation of NF-κB-dependent pathways. However, HBD-1 is thought to be expressed constitutively, and its association with increased risk of HIV acquisition requires further investigation. Our finding of higher genital tract HNP 1–3 levels at acute infection could reflect recruitment of degranulating neutrophils by IL-8, MIP-3α, and other proinflammatory mediators that may promote activation of NF-κB and recruitment of HIV target cells. The correlation between CVL HNP 1–3 and plasma viral set point suggests that concentrations of defensins at the genital mucosa during acute HIV infection could impact long-term HIV progression and underscores the relationship between mucosal inflammatory cytokine profiles and viral set point described in prior CAPRISA 002 studies.

The limitations of this small study are that we do not have detailed information about the vaginal microbiota, and white blood cell quantification was not available from samples for which Nugent scores were performed. There are several important variables, such as sexual behaviors, intravaginal practices, phase of menstrual cycle, and genital tract pathogens (other than those for which participants were tested) that may have impacted our results. Moreover, the dilutional effect of CVL may have limited our ability to detect molecules present in low concentrations. Despite these limitations, this study describes a significant association between E. coli inhibitory activity and HIV acquisition risk. This inexpensive and noninvasive assay may provide a feasible biomarker of HIV seroconversion risk in populations of women with a higher prevalence of subclinical or clinical BV, and the combination of this biomarker with concentrations of SLPI and defensins may increase predictive value. If validated in larger studies, this assay may be useful to identify women most in need of prevention strategies and to screen potential subjects for HIV prevention studies. Identifying the host and microbial mediators that contribute to this activity could also inform the development of effective HIV preexposure prophylaxis strategies.

Acknowledgments

This work was supported by Public Health Service Grants K25AI089271 and AI051519. The CAPRISA 002 Acute Infection Study was part of the Comprehensive International Program of Research on AIDS (CIPRA) of the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH) Grant AI51794 and received support from the South African Department of Science and Technology and the National Research Foundation Grant 67385. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

Author Disclosure Statement

No competing financial interests exist.

References


Address correspondence to:
Rebecca Pellett Madan
Department of Pediatrics
Albert Einstein College of Medicine
1300 Morris Park Avenue, Forchheimer 702D
Bronx, New York, 10461
E-mail: rebecca.madan@einstein.yu.edu